Abstract
Malignant Mesothelioma is an aggressive and fatal type of tumor. The incidence of mesothelioma has increased in the past 30 years and is now common as male cancers of the liver, bone and bladder, especially in Europe and Australia. The main risk factor is asbestos exposure even if other co-factor, such as simian virus 40 (SV40) could be implied in its etiology. Unfortunately, its incidence is expected to continue to increase for the next decades, also in rapidly industrializing countries, such as India, where it is not recognised as an occupational disease. Furthermore, some disastrous events, such as the World Trade Center Disaster, may contribute to increase future risk for mesothelioma. The treatment-resistant phenotype of mesothelioma is largely due to its ability to escape from the highly regulated apoptotic machinery. The understanding of the molecular mechanisms responsible of the malignant mesothelioma resistance to apoptosis is now advancing, allowing developing new therapeutic strategies to change the natural history and improve survival of patients. This review gives an overview of the main anti-apoptotic strategies devised by malignant mesothelioma and the therapeutic implication and opportunities for this cancer.
Keywords: Malignant mesothelioma, apoptosis, death receptors, bcl-2 family proteins, IAPs, growth factors, therapy
Current Medicinal Chemistry
Title: Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Volume: 15 Issue: 7
Author(s): M. R. Rippo, F. Villanova and A. Procopio
Affiliation:
Keywords: Malignant mesothelioma, apoptosis, death receptors, bcl-2 family proteins, IAPs, growth factors, therapy
Abstract: Malignant Mesothelioma is an aggressive and fatal type of tumor. The incidence of mesothelioma has increased in the past 30 years and is now common as male cancers of the liver, bone and bladder, especially in Europe and Australia. The main risk factor is asbestos exposure even if other co-factor, such as simian virus 40 (SV40) could be implied in its etiology. Unfortunately, its incidence is expected to continue to increase for the next decades, also in rapidly industrializing countries, such as India, where it is not recognised as an occupational disease. Furthermore, some disastrous events, such as the World Trade Center Disaster, may contribute to increase future risk for mesothelioma. The treatment-resistant phenotype of mesothelioma is largely due to its ability to escape from the highly regulated apoptotic machinery. The understanding of the molecular mechanisms responsible of the malignant mesothelioma resistance to apoptosis is now advancing, allowing developing new therapeutic strategies to change the natural history and improve survival of patients. This review gives an overview of the main anti-apoptotic strategies devised by malignant mesothelioma and the therapeutic implication and opportunities for this cancer.
Export Options
About this article
Cite this article as:
Rippo R. M., Villanova F. and Procopio A., Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies, Current Medicinal Chemistry 2008; 15 (7) . https://dx.doi.org/10.2174/092986708783885273
DOI https://dx.doi.org/10.2174/092986708783885273 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Safety of Nanoparticles in Medicine
Current Drug Targets Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Design and Synthesis of Small Molecule Carbonic Anhydrase IX Inhibitors
Current Topics in Medicinal Chemistry Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry New Scope of Targeted Therapies in Lung Carcinoma
Mini-Reviews in Medicinal Chemistry A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design